Please Wait
Applying Filters...
menu
    • menu
    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Solriamfetol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,107Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Axsome Presents Data from Multiple Programs at Sleep Europe 2024
    Axsome Presents Data from Multiple Programs at Sleep Europe 2024

    24 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2952012/33090/en/Axsome-Therapeutics-Presents-Data-from-Multiple-Programs-at-Sleep-Europe-2024.html

    GLOBENEWSWIRE
    24 Sep 2024
    Share Share
    Axsome Settles Sunosi Patent Litigation With Sandoz
    Axsome Settles Sunosi Patent Litigation With Sandoz

    21 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/21/2933398/33090/en/Axsome-Therapeutics-Reaches-Agreement-to-Dismiss-Sunosi-Solriamfetol-Patent-Litigation-with-Sandoz-Inc.html

    GLOBENEWSWIRE
    21 Aug 2024
    Share Share
    Axsome Initiates Ph 3 Trial of Solriamfetol for Binge Eating Disorder
    Axsome Initiates Ph 3 Trial of Solriamfetol for Binge Eating Disorder

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855085/33090/en/Axsome-Therapeutics-Initiates-ENGAGE-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Binge-Eating-Disorder.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    Axsome Hosts Solriamfetol Investor Event with Expert Thought Leaders Today
    Axsome Hosts Solriamfetol Investor Event with Expert Thought Leaders Today

    07 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/07/2792365/33090/en/Axsome-Therapeutics-Hosts-Solriamfetol-Virtual-Investor-Event-with-Expert-Thought-Leaders-Today.html

    GLOBENEWSWIRE
    07 Dec 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Solriamfetol Hydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Solriamfetol Hydrochloride

    08 Aug 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-solriamfetol-hydrochloride-98059.pdf

    FDA
    08 Aug 2023
    Share Share
    Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol
    Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol

    07 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/07/2701004/33090/en/Axsome-Therapeutics-Initiates-FOCUS-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorder-ADHD-in-Adults.html

    GLOBENEWSWIRE
    07 Jul 2023
    Share Share